Cardiol Therapeutics Inc.Cardiol Therapeutics Inc.Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc.

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪161.72 M‬USD
−0.34USD
‪−21.22 M‬USD
‪65.19 M‬
Beta (1Y)
1.02

About CARDIOL THERAPEUTICS INC

CEO
David G. Elsley
Headquarters
Oakville
Founded
2017
FIGI
BBG00N2N8310
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of CRDL is 2.35 USD — it has increased by 5.38% in the past 24 hours. Watch Cardiol Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Cardiol Therapeutics Inc. stocks are traded under the ticker CRDL.
CRDL stock has fallen by 2.08% compared to the previous week, the month change is a 27.72% rise, over the last year Cardiol Therapeutics Inc. has showed a 256.06% increase.
We've gathered analysts' opinions on Cardiol Therapeutics Inc. future price: according to them, CRDL price has a max estimate of 8.98 USD and a min estimate of 3.10 USD. Watch CRDL chart and read a more detailed Cardiol Therapeutics Inc. stock forecast: see what analysts think of Cardiol Therapeutics Inc. and suggest that you do with its stocks.
CRDL reached its all-time high on Feb 25, 2019 with the price of 10.00 USD, and its all-time low was 0.45 USD and was reached on Apr 5, 2023. View more price dynamics on CRDL chart.
See other stocks reaching their highest and lowest prices.
CRDL stock is 7.56% volatile and has beta coefficient of 1.02. Track Cardiol Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Cardiol Therapeutics Inc. there?
Today Cardiol Therapeutics Inc. has the market capitalization of ‪160.01 M‬, it has increased by 12.23% over the last week.
Yes, you can track Cardiol Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Cardiol Therapeutics Inc. is going to release the next earnings report on Aug 13, 2024. Keep track of upcoming events with our Earnings Calendar.
CRDL earnings for the last quarter are −0.10 USD per share, whereas the estimation was −0.09 USD resulting in a −16.98% surprise. The estimated earnings for the next quarter are −0.08 USD per share. See more details about Cardiol Therapeutics Inc. earnings.
Cardiol Therapeutics Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 0 USD.
CRDL net income for the last quarter is ‪−6.78 M‬ USD, while the quarter before that showed ‪−5.76 M‬ USD of net income which accounts for −17.60% change. Track more Cardiol Therapeutics Inc. financial stats to get the full picture.
No, CRDL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CRDL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Cardiol Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Cardiol Therapeutics Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Cardiol Therapeutics Inc. stock shows the strong buy signal. See more of Cardiol Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.